Supplement:

Accident and emergency (AE) attendance in England following infection with SARS-CoV-2 Omicron or Delta

Table of Contents

1.	Further information on OpenSAFELY	2
2.	Details on data sources	3
3.	Definition of comorbidities	4
4.	Complete demographic and clinical characteristics	6
5.	Theoretical causal pathway design, directed acyclic graph (DAG)	8
6. vaco	Absolute risk of AE attendance following diagnosis of Omicron and Delta stratified by age, cination, and comorbidity status	9
7.	References	10

1. Further information on OpenSAFELY

All data were linked, stored and analysed securely within the OpenSAFELY platform https://opensafely.org/. The dataset analysed within OpenSAFELY is based on 24 million people currently registered with GP surgeries using TPP SystmOne software. Data include pseudonymized data such as coded diagnoses, medications and physiological parameters. No free text data are included. All code is shared openly for review and re-use under MIT open license (https://github.com/opensafely/SGTF-Omi). Detailed pseudonymised patient data is potentially reidentifiable and therefore not shared. We rapidly delivered the OpenSAFELY data analysis platform without prior funding to deliver timely analyses on urgent research questions in the context of the global Covid-19 health emergency: now that the platform is established we are developing a formal process for external users to request access in collaboration with NHS England; details of this process will be published shortly on OpenSAFELY.org.

Information governance and ethics

NHS England is the data controller; TPP is the data processor; and the key researchers on OpenSAFELY are acting on behalf of NHS England. This implementation of OpenSAFELY is hosted within the TPP environment which is accredited to the ISO 27001 information security standard and is NHS IG Toolkit compliant;^{1,2} patient data has been pseudonymised for analysis and linkage using industry standard cryptographic hashing techniques; all pseudonymised datasets transmitted for linkage onto OpenSAFELY are encrypted; access to the platform is via a virtual private network (VPN) connection, restricted to a small group of researchers; the researchers hold contracts with NHS England and only access the platform to initiate database queries and statistical models; all database activity is logged; only aggregate statistical outputs leave the platform environment following best practice for anonymisation of results such as statistical disclosure control for low cell counts.3 The OpenSAFELY research platform adheres to the obligations of the UK General Data Protection Regulation (GDPR) and the Data Protection Act 2018. In March 2020, the Secretary of State for Health and Social Care used powers under the UK Health Service (Control of Patient Information) Regulations 2002 (COPI) to require organisations to process confidential patient information for the purposes of protecting public health, providing healthcare services to the public and monitoring and managing the COVID-19 outbreak and incidents of exposure; this sets aside the requirement for patient consent.⁴ Taken together, these provide the legal bases to link patient datasets on the OpenSAFELY platform. GP practices, from which the primary care data are obtained, are required to share relevant health information to support the public health response to the pandemic, and have been informed of the OpenSAFELY analytics platform.

This study was approved by the Health Research Authority (REC reference 20/LO/0651) and by the LSHTM Ethics Board (reference 21863).

2. Details on data sources

We used several linked data sets in this analysis (Table S1).

Data	Description
SARS-CoV-2 tests	Positive and negative tests of people tested under the UK's Pillar 1 and Pillar 2 testing schemes are reported. Pillar 2 generally is community tests and Pillar 1 is tests in hospital (patients and health care workers). Only some of the labs used for testing in England use the 3 channel PCR for which a "failure to detect the Spike-gene target" is indicative of the VOC, therefore not all positive tests have known SGTF status. The data come from Public Health England's (PHE) Second Generation Surveillance System.
General Practitioner (GP) data	GP data are drawn from patients who are registered at a practice that runs the TPP SystmOne (https://www.tpp-uk.com/products/systmone). This is approximately 40% of GPs in England. Each patient encounter with a GP is coded using CTV3 codes, which fully aligns with SNOMED-CT which describe the reason for the encounter, and these codes are used to define the health history of each individual. Prescribed medications are also stored in the health record. Demographic data such as age and ethnicity are collected by GPs, as are some behavioural data like whether an individual smokes.
Hospital admission	Secondary Uses Statistics (SUS) data used to define hospital admission and ICU admission. Data are collected on hospital admissions with ICD-10 codes for conditions, and procedural codes for treatment. Whether the patient is admitted to intensive care during their hospital admission is also included. (https://digital.nhs.uk/services/secondary-uses-service-sus)
Emergency care	The Emergency Care Data Set (ECDS) is the national data set for urgent and emergency care. ECDS is part of Hospital Episode Statistics (HES) and is provided to OpenSAFELY via NHS Digital's Secondary Use Service (SUS). (https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data-sets/emergency-care-data-set-ecds)
Mortality date	The date of death plus codes for the cause of death are from the Office for National Statistics. We only use date of death in this study.
Vaccination date	The date, dose number, vaccine manufacturer and batch are entered into their health record. We only use the date of administration of the first dose in this study.
Index of multiple deprivation (IMD)	We use the England IMD which is matched to individuals at the postcode level.
Urban/Rural classification	We use 5 categories of Urban/Rural classifications which are matched to individuals at the postcode level.

Table S1. Data sources used in this analysis.

3. Definition of comorbidities

A patient is identified as having a comorbidity if their health record includes codes indicative of each of the conditions (Table S2).

Condition	Codelist defining presence of comorbidity
Aplastic anaemia	https://codelists.opensafely.org/codelist/opensafely/aplastic-anaemia/
	https://codelists.opensafely.org/codelist/opensafely/asplenia/
Asplenia	https://codelists.opensafely.org/codelist/opensafely/asthma-
Asthma	diagnosis/
	https://codelists.opensafely.org/codelist/opensafely/asthma-inhaler-
	salbutamol-medication/2020-04-15/
	https://codelists.opensafely.org/codelist/opensafely/asthma-inhaler-
	steroid-medication/2020-04-15/
	https://codelists.opensafely.org/codelist/opensafely/asthma-oral-
Bone marrow transplant	prednisolone-medication/2020-04-27/
·	https://codelists.opensafely.org/codelist/opensafely/bone-marrow-
Cancer	transplant/2020-04-15/
	https://codelists.opensafely.org/codelist/opensafely/cancer-excluding-
	lung-and-haematological/2020-04-15/
	https://codelists.opensafely.org/codelist/opensafely/chemotherapy-
	or-radiotherapy-updated/2020-04-15/
	https://codelists.opensafely.org/codelist/opensafely/haematological-
Chronic cardiac disease	cancer/2020-04-15/
	https://codelists.opensafely.org/codelist/opensafely/lung-
Chronic respiratory	cancer/2020-04-15/
disease	https://codelists.opensafely.org/codelist/opensafely/chronic-cardiac-
	disease/2020-04-08/
	https://codelists.opensafely.org/codelist/opensafely/chronic-
Chronic liver disease	respiratory-disease/2020-04-10/
om om o nver alsease	https://codelists.opensafely.org/codelist/opensafely/chronic-liver-
Dementia	disease/2020-06-02/
Demenda	https://codelists.opensafely.org/codelist/opensafely/dementia/2020-
Diabetes	04-22/
Diabetes	https://codelists.opensafely.org/codelist/opensafely/diabetes/2020-
Chronic kidney disease	04-15/
chi onic Maricy disease	https://codelists.opensafely.org/codelist/opensafely/chronic-kidney-
GI bleed	disease/2020-04-14/
GI DICCU	https://codelists.opensafely.org/codelist/opensafely/gi-bleed-or-
HIV	ulcer/2020-04-08/
Permanent	https://codelists.opensafely.org/codelist/opensafely/hiv/2020-07-13/
immunosuppression	https://codelists.opensafely.org/codelist/opensafely/permanent-
Temporary	immunosuppression/2020-06-02/
immunosuppression	https://codelists.opensafely.org/codelist/opensafely/temporary-
Hypertension	immunosuppression/2020-04-24/
Tryper terision	https://codelists.opensafely.org/codelist/opensafely/hypertension/202
Stroke	0-04-28/
Stroke	https://codelists.opensafely.org/codelist/opensafely/stroke-
Inflammatory bowel	updated/2020-06-02/
disease	https://codelists.opensafely.org/codelist/opensafely/inflammatory-
	bowel-disease/2020-04-07/
Neurological conditions	<u> </u>

	https://codelists.opensafely.org/codelist/opensafely/other-
Psoriasis	neurological-conditions/2020-06-02/
	https://codelists.opensafely.org/codelist/opensafely/ra-sle-
Sickle cell disease	psoriasis/2020-04-14/
	https://codelists.opensafely.org/codelist/opensafely/sickle-cell-
	disease/2020-04-14/
Smoking	https://codelists.opensafely.org/codelist/opensafely/smoking-
	clear/2020-04-29/
Organ transplant	https://codelists.opensafely.org/codelist/opensafely/smoking-
	<u>unclear/2020-04-29/</u>
	https://codelists.opensafely.org/codelist/opensafely/solid-organ-
	transplantation/2020-04-10/

Table S2. Comorbidities and the codelists that determine if a patient is classified as having that comorbidity. All codelists are reviewed by clinicians.


4. Complete demographic and clinical characteristics

	Total N (%)	Delta N (%)	Omicron N (%)
Total population	330,380	92,950	237,430
AE attendances	660 (0.2)	319 (0.3)	341 (0.1)
Leading to admission	190 (0.1)	125 (0.1)	65 (0.0)
Time to AE attendance	·		
Days, median (IQR)	5.0 (2.0-8.0)	5.0 (3.0-8.0)	4.0 (2.0-8.0)
Follow-up time	·		
Days, median (IQR)	29.0 (24.0-36.0)	39.0 (34.0-43.0)	26.0 (23.0-31.0)
Epidemiological week of diagnosi	S		
05Dec-11Dec	42,691 (12.9)	39,317 (42.3)	3,374 (1.4)
12Dec-18Dec	63,870 (19.3)	30,881 (33.2)	32,989 (13.9)
19Dec-25Dec	96,025 (29.1)	15,980 (17.2)	80,045 (33.7)
26Dec-01Jan	127,794 (38.7)	6,772 (7.3)	121,022 (51.0)
Sex	·		
Female	170,098 (51.5)	47,799 (51.4)	122,299 (51.5)
Age			
Years, median (IQR)	34.0 (22.0-48.0)	32.0 (11.0-44.0)	35.0 (24.0-49.0)
Age group	<u>'</u>		
0-39	199,764 (60.5)	60,497 (65.1)	139,267 (58.7)
40-54	81,761 (24.7)	23,262 (25.0)	58,499 (24.6)
55-64	31,750 (9.6)	6,730 (7.2)	25,020 (10.5)
65-74	11,607 (3.5)	1,729 (1.9)	9,878 (4.2)
75-84	4,453 (1.3)	580 (0.6)	3,873 (1.6)
85+	1,045 (0.3)	152 (0.2)	893 (0.4)
SARS-CoV-2 vaccination status at	diagnosis		
Unvaccinated	80,499 (24.4)	40,007 (43.0)	40,492 (17.1)
First dose	20,486 (6.2)	6,187 (6.7)	14,299 (6.0)
Second dose	169,684 (51.4)	42,027 (45.2)	127,657 (53.8)
Booster	59,711 (18.1)	4,729 (5.1)	54,982 (23.2)
Ethnicity, in 5 categories			
White	213,109 (64.5)	61,072 (65.7)	152,037 (64.0)
South Asian	16,112 (4.9)	3,916 (4.2)	12,196 (5.1)
Black	7,025 (2.1)	1,149 (1.2)	5,876 (2.5)
Mixed	4,551 (1.4)	1,186 (1.3)	3,365 (1.4)
Other	4,018 (1.2)	1,023 (1.1)	2,995 (1.3)
Missing	85,565 (25.9)	24,604 (26.5)	60,961 (25.7)
Evidence of obesity (missing set to		. ,	,
No record of obesity	273,603 (82.8)	79,587 (85.6)	194,016 (81.7)
Obese I (30-34.9)	35,543 (10.8)	8,214 (8.8)	27,329 (11.5)
Obese II (35-39.9)	14,201 (4.3)	3,409 (3.7)	10,792 (4.5)
Obese III (40+)	7,033 (2.1)	1,740 (1.9)	5,293 (2.2)
Smoking status (missing set to ne		, , ,	, ,
Never	206,862 (62.6)	63,098 (67.9)	143,764 (60.6)

Former	83,960 (25.4)	20,144 (21.7)	63,816 (26.9)
Current	39,558 (12.0)	9,708 (10.4)	29,850 (12.6)
Categorical number of comorbidities	1	·	·
No comorbidity	296,883 (89.9)	85,970 (92.5)	210,913 (88.8)
1 comorbidity	26,517 (8.0)	5,718 (6.2)	20,799 (8.8)
2+ comorbidities	6,980 (2.1)	1,262 (1.4)	5,718 (2.4)
Index of Multiple Deprivation (IMD)	'	·	
1 least deprived	67,072 (20.3)	19,304 (20.8)	47,768 (20.1)
2	66,028 (20.0)	18,250 (19.6)	47,778 (20.1)
3	64,845 (19.6)	17,619 (19.0)	47,226 (19.9)
4	67,320 (20.4)	18,115 (19.5)	49,205 (20.7)
5 most deprived	65,115 (19.7)	19,662 (21.2)	45,453 (19.1)
Categorical household size			
1-2	86,660 (26.2)	18,814 (20.2)	67,846 (28.6)
3-5	169,309 (51.2)	53,271 (57.3)	116,038 (48.9)
6-10	21,739 (6.6)	7,182 (7.7)	14,557 (6.1)
11+	1,636 (0.5)	373 (0.4)	1,263 (0.5)
Missing	51,036 (15.4)	13,310 (14.3)	37,726 (15.9)
Binary care home status ^c	'	·	
Private home	330,180 (99.9)	92,914 (100.0)	237,266 (99.9)
Care home	200 (0.1)	36 (0.0)	164 (0.1)
NHS England region			
East	73,990 (22.4)	22,131 (23.8)	51,859 (21.8)
East Midlands	61,328 (18.6)	18,856 (20.3)	42,472 (17.9)
London	23,374 (7.1)	3,288 (3.5)	20,086 (8.5)
North East	23,360 (7.1)	5,371 (5.8)	17,989 (7.6)
North West	39,290 (11.9)	11,581 (12.5)	27,709 (11.7)
South East	18,062 (5.5)	4,545 (4.9)	13,517 (5.7)
South West	17,568 (5.3)	6,053 (6.5)	11,515 (4.8)
West Midlands	13,224 (4.0)	3,853 (4.1)	9,371 (3.9)
Yorkshire and the Humber	60,034 (18.2)	17,243 (18.6)	42,791 (18.0)
Rural Urban in five categories			
Urban major conurbation	76,189 (23.1)	16,792 (18.1)	59,397 (25.0)
Urban minor conurbation	28,700 (8.7)	7,172 (7.7)	21,528 (9.1)
Urban city and town	164,778 (49.9)	49,727 (53.5)	115,051 (48.5)
Rural town and fringe	36,288 (11.0)	11,325 (12.2)	24,963 (10.5)
Rural village and dispersed	21,599 (6.5)	7,105 (7.6)	14,494 (6.1)
Missing	2,826 (0.9)	829 (0.9)	1,997 (0.8)

^a120,629 Missing values set to no evidence of obesity; ^b63,542 missing values set to never smoking status; ^cBased on address linkage with CQC data as of 1st Feb 2020: 2,826 missing values set to private home.

5. Theoretical causal pathway design, directed acyclic graph (DAG)



6. Absolute risk of AE attendance following diagnosis of Omicron and Delta stratified by age, vaccination, and comorbidity status

Comorbidities/Vax/Age group	Delta (95% CI)	Omicron (95% CI)
No Comorbidities		
Unvaccinated: 0-39	0.39 (0.31-0.47)	0.10 (0.06-0.14)
40-69	0.66 (0.48-0.84)	0.17 (0.10-0.24)
70+	1.42 (0.78-2.06)	0.37 (0.17-0.58)
First dose: 0-39	0.35 (0.18-0.52)	0.17 (0.09-0.25)
40-69	0.60 (0.28-0.91)	0.29 (0.14-0.44)
70+	1.29 (0.47-2.11)	0.63 (0.23-1.02)
Second dose: 0-39	0.14 (0.10-0.18)	0.08 (0.06-0.10)
40-69	0.23 (0.17-0.29)	0.13 (0.10-0.16)
70+	0.51 (0.28-0.74)	0.29 (0.16-0.42)
Booster: 0-39	0.11 (0.05-0.17)	0.05 (0.03-0.07)
40-69	0.19 (0.08-0.29)	0.09 (0.06-0.12)
70+	0.40 (0.16-0.65)	0.19 (0.12-0.27)
1 Comorbidity		
Unvaccinated: 0-39	0.92 (0.62-1.21)	0.24 (0.13-0.34)
40-69	1.55 (1.04-2.06)	0.41 (0.23-0.59)
70+	3.29 (1.79-4.79)	0.88 (0.39-1.37)
First dose: 0-39	0.83 (0.37-1.29)	0.40 (0.19-0.62)
40-69	1.41 (0.63-2.18)	0.69 (0.32-1.06)
70+	2.99 (1.10-4.88)	1.48 (0.55-2.41)
Second dose: 0-39	0.33 (0.20-0.45)	0.18 (0.12-0.25)
40-69	0.56 (0.38-0.73)	0.31 (0.22-0.41)
70+	1.20 (0.64-1.75)	0.68 (0.37-0.99)
Booster: 0-39	0.26 (0.10-0.42)	0.12 (0.08-0.17)
40-69	0.44 (0.19-0.69)	0.21 (0.14-0.28)
70+	0.95 (0.38-1.52)	0.46 (0.28-0.64)
2+ Comorbidities		
Unvaccinated: 0-39	1.78 (1.07-2.48)	0.47 (0.23-0.70)
40-69	2.98 (1.80-4.17)	0.80 (0.40-1.19)
70+	6.20 (3.59-8.82)	1.71 (0.80-2.62)
First dose: 0-39	1.61 (0.66-2.57)	0.79 (0.33-1.25)
40-69	2.71 (1.12-4.30)	1.34 (0.56-2.12)
70+	5.66 (2.28-9.03)	2.85 (1.13-4.57)
Second dose: 0-39	0.64 (0.35-0.92)	0.36 (0.21-0.51)
40-69	1.08 (0.66-1.51)	0.62 (0.38-0.85)
70+	2.32 (1.31-3.33)	1.33 (0.75-1.90)
Booster: 0-39	0.51 (0.18-0.83)	0.24 (0.13-0.36)
40-69	0.86 (0.34-1.38)	0.42 (0.25-0.58)
70+	1.85 (0.81-2.89)	0.90 (0.58-1.22)

7. References

- 1. BETA -Data Security Standards NHS Digital. NHS Digital. https://digital.nhs.uk/about-nhs-digital/our-work/nhs-digital-data-and-technology-standards/framework/beta---data-security-standards.
- 2. Data Security and Protection Toolkit NHS Digital. NHS Digital. https://digital.nhs.uk/data-and-information/looking-after-information/data-security-and-information-governance/data-security-and-protection-toolkit.
- 3. ISB1523: Anonymisation Standard for Publishing Health and Social Care Data NHS Digital. NHS Digital. https://digital.nhs.uk/data-and-information/information-standards/information-standa
- 4. Secretary of State for Health and Social Care UK Government. Coronavirus (COVID-19): notification to organisations to share information. 2020. https://web.archive.org/web/20200421171727/https://www.gov.uk/government/publications/coronavirus-covid-19-notification-of-data-controllers-to-share-information (accessed 26/2/2021.
- 5. Department of Health and Social Care. Guidance: COVID-19 testing data: methodology note. 21/8/2020 2020. https://www.gov.uk/government/publications/coronavirus-covid-19-testing-data-methodology-note (accessed 25/2/2021.
- 6. Curtis HJ, MacKenna B, Croker R, et al. OpenSAFELY NHS Service Restoration Observatory 1: describing trends and variation in primary care clinical activity for 23.3 million patients in England during the first wave of COVID-19. *medRxiv* 2021: 2021.01.06.21249352.